Trial Condition(s):

Prevention of venous thromboembolism after MOS

BAY59-7939,Dose proportionality II for SPAF

Bayer Identifier:

12362

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2009-012008-14

EU CT Number:

Not Available

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

July2009

August2009

Phase

Could I receive a placebo?

Products

Xarelto (Rivaroxaban, BAY59-7939)

Accepts Healthy Volunteers

N/A

Where to Participate

Locations

Locations
Locations CRS Clinical-Research-Services Mannheim GmbH Mannheim, Germany, 68167	Contact Us: E-mail: [email protected] Phone: Not Available

CRS Clinical-Research-Services Mannheim GmbH

Mannheim, Germany, 68167

Contact Us:

E-mail: [email protected]

Phone: Not Available

Prevention of venous thromboembolism after MOS

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

18 Years

45 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information